Visit from Dr. Bernard Ludwig (Preciphos)
On May 5th, we had the pleasure of welcoming Dr. Bernard Ludwig, CEO of Preciphos, to our laboratories. The visit centered on exploring collaborative opportunities in the field of aptamer selection.
Preciphos is a French biotech company specializing in the development of portable, multiplexed in-vitro diagnostic (IVD) devices. Their technology enables rapid, point-of-care detection of autoimmune and inflammatory biomarkers using minimal blood samples. This approach aims to enhance precision medicine, particularly in cardiovascular disease risk assessment and management.
Dr. Ludwig's visit provided valuable insights into integrating aptamer-based detection methods into Preciphos's diagnostic platforms. We look forward to potential collaborations that combine our expertise in aptamer technology with Preciphos's innovative diagnostic solutions.
Compartir
